DRNA - Dicerna Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.58
+0.76 (+5.93%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close12.82
Open12.83
Bid0.00 x 800
Ask0.00 x 1400
Day's Range12.60 - 13.71
52 Week Range6.80 - 17.98
Volume352,473
Avg. Volume696,578
Market Cap851.899M
Beta (3Y Monthly)3.05
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.92
Trade prices are not sourced from all markets
  • Business Wire10 days ago

    Dicerna to Participate in Upcoming Investor Conferences

    Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in three investor conferences in November. Dr. Fambrough will present a corporate update and overview of the Company’s most advanced GalXC™ pipeline programs, including DCR-PHXC, an investigational RNAi therapeutic in development for the treatment of all forms of primary hyperoxaluria. A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com.

  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of DRNA earnings conference call or presentation 5-Nov-18 9:30pm GMT

    Q3 2018 Dicerna Pharmaceuticals Inc Earnings Call

  • Dicerna Pharmaceuticals (DRNA) Reports Q3 Loss, Misses Revenue Estimates
    Zacks10 days ago

    Dicerna Pharmaceuticals (DRNA) Reports Q3 Loss, Misses Revenue Estimates

    Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -45.83% and -7.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press10 days ago

    Dicerna Pharmaceuticals: 3Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 35 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • Business Wire10 days ago

    Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update

    Demonstrated Clinical POC for DCR-PHXC in Primary Hyperoxaluria and On Track to Initiate Registration Trial in Q1 2019

  • Investopedia15 days ago

    3 Pharma Stocks to Make a Portfolio Feel Better

    In a speech at the U.S. Department of Health and Human Services (HHS) on Oct. 25, President Trump detailed how he intends to reduce pharmaceutical prices. Because pharmacy drugs are exempt from the plan at this stage, the impact on pharmaceutical companies is likely to be minimal. However, investors should keep up to date with further developments relating to the Trump administration's blueprint to lower drug prices, which was released in May.

  • Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal
    Zacks16 days ago

    Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal

    Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

  • Business Wire17 days ago

    Dicerna to Report Third Quarter 2018 Financial Results and Host Conference Call on November 5, 2018

    Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2018 financial results after market close on Monday, November 5, 2018. Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The webcast will also be archived on the Company's website.

  • Benzinga18 days ago

    Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal

    Eli Lilly And Co (NYSE: LLY) announced Monday it entered into a licensing and research collaboration with Dicerna, under which both companies will focus on discovery, development and commercialization drugs for cardio-metabolic diseases as well as for neurodegeneration and pain using the latter's GalXC RNAi technology platform. For licensing its platform, Dicerna stands to receive an upfront payment of $100 million as well as an equity investment of $100 million at a premium.

  • MarketWatch18 days ago

    Dicerna's stock rockets after licensing, research collaboration with Eli Lilly

    Shares of Dicerna Pharmaceuticals Inc. rocketed 42% in premarket trade Monday, after the company said it will receive an upfront payment of $100 million as part of a licensing and research collaboration with Eli Lilly & Co. , to develop new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. Eli Lilly's stock was still inactive ahead of the open. Under terms of the deal, Eli Lilly has also made an equity investment of $100 million at a premium, and Dicerna will be eligible to receive up to $350 million per target in development and commercialization milestones. ""We are excited to collaborate with Dicerna and utilize their RNAi expertise to study targets that up until now have proven to be very technically challenging," said Eli Lilly Chief Scientific Officer Daniel Skovronsky. Dicerna shares have rallied 44% year to date through Friday, while Lilly's stock has climbed 26% and the S&P 500 has slipped 0.6%.

  • Lilly and Dicerna Announce RNAi Licensing and Research Collaboration
    PR Newswire18 days ago

    Lilly and Dicerna Announce RNAi Licensing and Research Collaboration

    INDIANAPOLIS and CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Dicerna Pharmaceuticals (DRNA) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna's proprietary GalXC™ RNAi technology platform to progress new drug targets toward clinical development and commercialization.

  • Drug giant Lilly backs Cambridge's Dicerna in $200M deal
    American City Business Journals18 days ago

    Drug giant Lilly backs Cambridge's Dicerna in $200M deal

    The Cambridge biotech is eligible to earn up to $3.7 billion through the deal, with $200 million upfront.

  • Reuters18 days ago

    Eli Lilly makes bet on gene-silencing drug firm Dicerna

    Eli Lilly and Co is spending $100 million for a stake in Dicerna Pharmaceuticals Inc as part of a licensing deal, making it the latest major drugmaker to bet on gene-silencing technology. The companies expect to collaborate on developing more than 10 experimental drugs to treat pain, neuro-degenerative diseases and cardio-metabolic disorders. For the use of Dicerna's GalXC gene-silencing platform, Lilly will pay the company $100 million upfront and buy a $100 million equity stake at a per share price of $18.47, a 42 percent premium to Dicerna's close on Friday, Dicerna told Reuters.

  • Business Wire22 days ago

    Dicerna Announces Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 (PH1 and PH2)

    Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the presentation of late-breaking data from its ongoing PHYOX Phase 1 trial, in which single-dose administration of DCR-PHXC, the Company’s lead GalXC™ product candidate, was associated with normalization or near-normalization of urinary oxalate levels in a majority of adult patients with primary hyperoxaluria types 1 and 2 (PH1 and PH2). In a poster presented at the American Society of Nephrology (ASN) Annual Kidney Week 2018 in San Diego, Calif., investigators reported that a single 3.0-mg/kg dose of DCR-PHXC brought urinary oxalate levels into the normal range (defined as 24-hour excretion ≤0.46 mmol) at one or more post-dose time points in three of four participants, including a mean maximal reduction in 24-hour urinary oxalate of 65%.

  • Alexion Pharmaceuticals Inc (ALXN) Q3 2018 Earnings Conference Call Transcript
    Motley Fool22 days ago

    Alexion Pharmaceuticals Inc (ALXN) Q3 2018 Earnings Conference Call Transcript

    ALXN earnings call for the period ending September 30, 2018.

  • Investor's Business Daily22 days ago

    Big Cap 20 Biotech Stock Dives On Mixed Third-Quarter Revenue

    Alexion posted an "impressive" 54% operating margin in the third quarter, leading to a big beat on adjusted earnings, but shares slid Wednesday as revenue missed some estimates.

  • Alexion enters RNA gene-silencing field with $637M Dicerna deal
    American City Business Journals23 days ago

    Alexion enters RNA gene-silencing field with $637M Dicerna deal

    Newly Massachusetts-based biotech Alexion Pharmaceuticals became the latest company to enter the gene silencing drug field, signing a deal with Dicerna Pharmaceuticals worth upwards of $637 million.

  • MarketWatch23 days ago

    Alexion stock rises 3% on Q3 beats, upbeat 2018 guidance

    Alexion Pharmaceuticals Inc. shares surged 3% in Wednesday premarket trade after the company reported third-quarter profit and revenue beats and upbeat 2018 guidance. Earnings for the latest quarter rose to $330.9 million, or $1.47 per share, from $78 million, or 35 cents per share in the year-earlier period. Adjusted earnings-per-share were $2.02, compared with the FactSet consensus of $1.74. Revenue rose to $1.03 billion from $859 million, above the FactSet consensus of $1.02 billion. The latest results include major sales increases for the company's Soliris, Strensiq and Kanuma medications. Soliris and Kanuma sales beat the FactSet consensus, while Strensiq sales missed. Alexion now expects 2018 revenue of $4.02 billion to $4.05 billion, an increase from previous guidance of $3.98 billion to $4.01 billion, and 2018 adjusted EPS of $7.45 to $7.60, an increase from prior guidance of $7.00 to $7.15. Alexion also announced a collaboration with Dicerna Pharmaceuticals Inc. to develop a category of promising medications called RNA interference therapies. Dicerna will receive an upfront payment of $22 million and a $15 million equity investment from Alexion, and will be eligible for various milestone payments and royalties. Alexion shares have dropped 9.1% over the last three months, compared with a 2.8% decline in the S&P 500 and a 0.2% decline in the Dow Jones Industrial Average .

  • Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases
    Business Wire23 days ago

    Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases

    - Collaboration provides opportunity to build on Alexion’s more than two decades of complement leadership with expansion into RNAi-based therapies using Dicerna’s GalXC™ technology

  • GlobeNewswire24 days ago

    New Research Coverage Highlights MEDIFAST INC, Palo Alto Networks, Salesforce, Agile Therapeutics, Dicerna Pharmaceuticals, and Corbus Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wirelast month

    Dicerna Announces Late-Breaking Data from the PHYOX Phase 1 Clinical Trial of DCR-PHXC Will Be Presented at ASN Kidney Week 2018

    Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that late-breaking data from the PHYOX Phase 1 trial of DCR-PHXC for the treatment of primary hyperoxaluria will be presented at the American Society of Nephrology Annual Kidney Week 2018, being held October 23-28 in San Diego.

  • Business Wire2 months ago

    Dicerna to Participate in Two Upcoming Investor Conferences

    Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences in October.

  • Why Dicerna Pharmaceuticals Stock Rose 7.7% Yesterday
    Market Realist2 months ago

    Why Dicerna Pharmaceuticals Stock Rose 7.7% Yesterday

    On September 13, Dicerna Pharmaceuticals (DRNA) stock rose 7.71% to $16.62 from its previous day’s close of $15.43. In the trial, Dicerna’s lead drug candidate, DCR-PHXC, showed that it was capable of bringing urinary oxalate levels to a normal or near-normal range in individuals with primary hyperoxaluria type 1 and hyperoxaluria type 2. The company is conducting studies with DCR-PHXC and investigating its potential as a therapy for all forms of hyperoxaluria.

  • Bluebird Bio Stock May Have Upside of at Least 60 Percent
    InvestorPlace2 months ago

    Bluebird Bio Stock May Have Upside of at Least 60 Percent

    Just as Bluebird Bio (NASDAQ:BLUE) started gaining traction in the markets in August, the stock erased all those gains since the start of September. And the month is hardly over. Why did BLUE stock fall 12% last week when the company did not issue any news that would explain what changed, fundamentally?